Polyrizon begins BZDs studies for treating ARS and status epilepticus

Polyrizon (PLRZ) announced the initiation of preclinical studies for intranasal Benzodiazepines BZDs , a first-line treatment for acute repetitive seizures or ARS and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization WHO , epilepsy is a neurological condition affecting about 50M people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse effects…The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board…”Launching this preclinical program marks an important milestone in our initiative to improve emergency treatment options for epilepsy patients,” said Tomer Izraeli, CEO of Polyrizon. “We believe our intranasal delivery platform has the potential to offer a faster, safer and more accessible solution for managing acute seizures outside of clinical settings.”